Interstitial inflammation in the entire cortical parenchyma in areas w/ and w/o fibrosis identifies at risk SLE pts for CKD progression. Abs 0634 #ACR22 @RheumNow https://t.co/3iBYHPyYXL https://t.co/iSwblT2Amm

Analysis from Abs 0954 shows that mainly fatigue and back pain have an impact on the mean BASDAI during pregnancy. #ACR22 @RheumNow https://t.co/l5VGKqF2ar https://t.co/fpkl8VRRJP

QD205 - RA Activity During Pregnancy (abstract #0955) #ACR22 28 yoF with active RA during Pregnancy - What are your treatment options? https://t.co/jj99qjugFG https://t.co/vioX8xZw0D

Dr PMease et al looked into impact of TNFi cycling in their #axSpA cohort: 💠After 6mos on 2nd TNFi, only 15% had ASDAS-LDA, 7% MCID in ASDAS, 8% >50% improvement 💠Cycling to 2nd TNFi limited benefits ⬇️sample size, worth further investigation #ACR22 @RheumNow ABST#1499 https://t.co/OVJxezdipW

Sjogren’s is tough to study, isn’t it? LOUiSSe (remibrutinib proof-of-concept SjS) - benefit with: - ESSDAI (primary, obj dx activity) ✅ - auto-Ab ✅ - all patient outcomes ❎ Has already exceeded many attempts Even then, still some limitations ABST1113 #ACR22 @RheumNow https://t.co/NlBaFVuuPa

VEXAS Abs 0823 #ACR22: Pulmonary disease is common VEXAS, frequently pulmonary infiltrates. It remains unclear if respiratory manifestations are part of the primary disease or a co-existing condition. What are you seeing in clinical practice? @RheumNow https://t.co/VBVKLIrsqq https://t.co/QhxtCdNi5v

Ab1113 #ACR22 Remibrutinib (LOU064, BTK inhib) in Sjogren's Will there be new Rx for Sjo? T Dorner: 73 pts Ph2 BTK 100mg BID/100 QD/PBO Better ESSDAI at wk 24 (p=0.003) Unstim saliv flow: improved vs PBO, not stat signif Decreased CXCL13 chemokine PROs not improved @RheumNow https://t.co/hJp33JPpHt

FOREMOST results: Early oligoarticular PsA pts experienced high disease burden/decreased QoL. Small joint involvement, although less commonly seen in oligoarticular PsA, was the most frequently observed pattern. Abs 1018 #ACR22 @RheumNow https://t.co/wBldKM9MTq https://t.co/qOVZd8aTyR

"If I had one test in a difficult case of suspected PMR, it would be PET/CT" - @LCalabreseDO #ACR22 @RheumNow (credit: as heard by @drceowen) https://t.co/w88peUd4j1

DANBIO registry plenary Abs 1112 finds 1 yr retention following a mandatory nationwide infliximab biosimilar-to-biosimilar switch was high. Retention higher in originator-experienced and in pts w/ low disease activity. #ACR22 @RheumNow https://t.co/ZAV2dcVzXl https://t.co/Kti2bZ1pkZ